Recursion Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXRX research report →
About the company
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
- CEO
- Najat Khan
- IPO
- 2021
- Employees
- 800
- HQ
- Salt Lake City, UT, US
Price Chart
- Market Cap
- $1.70B
- P/E
- -3.17
- P/S
- 25.64
- P/B
- 1.96
- EV/EBITDA
- -2.33
- Div Yield
- 0.00%
- Gross Margin
- -34.44%
- Op Margin
- -882.92%
- Net Margin
- -844.46%
- ROE
- -54.32%
- ROIC
- -47.11%
- Revenue
- $74.68M · 26.92%
- Net Income
- $-644,759,000 · -39.06%
- EPS
- $-1.44 · 14.79%
- Op Income
- $-648,132,000
- FCF YoY
- -1.45%
- 52W High
- $7.18
- 52W Low
- $2.77
- 50D MA
- $3.32
- 200D MA
- $4.10
- Beta
- 1.00
- Avg Volume
- 17.31M
Get TickerSpark's AI analysis on RXRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Dar Zavain | other | 5,109 |
| Jul 1, 26 | Li Dean Y | other | 3,747 |
| Jun 17, 26 | Borgeson Blake | other | 88,424 |
| Jun 17, 26 | HERSHBERG ROBERT | other | 88,424 |
| Jun 17, 26 | Michor Franziska | other | 88,424 |
| Jun 17, 26 | Sun Elaine D | other | 88,424 |
| Jun 17, 26 | Dar Zavain | other | 88,424 |
| Jun 17, 26 | Li Dean Y | other | 88,424 |
| Jun 17, 26 | Bumpus Namandje | other | 88,424 |
| Jun 18, 26 | Bumpus Namandje | sell | 3,963 |
Our RXRX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RXRX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.